FDA warning to Dr Reddy's Mexican unit will have limited business impact
This article was originally published in Scrip
Executive Summary
The US FDA's warning letter to Dr Reddy's Laboratories' Mexican intermediates and active pharmaceutical ingredients facility over good manufacturing practice (GMP) deviations is expected to have a limited impact on the firm's earnings at least for now, in view of the unit's low contribution to Dr Reddy's bottom line.